Sonoma Pharmaceuticals files updated investor presentation; no material new information disclosed

Sonoma Pharmaceuticals, Inc.

Filed Form 8-K with Item 7.01 disclosure attaching an updated investor presentation dated May 10, 2023.
Presentation covers Sonoma's stabilized hypochlorous acid (HOCl) products for dermatology, wound care, and other applications.
Company sells products directly or via partners in 55 countries; no specific financial results or guidance provided.
No changes in leadership, M&A, debt, litigation, or regulatory actions reported.
Forward-looking statements include risks typical of the business; no new material facts for investors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.